FierceHealthcare FierceHealthIT FierceMobileHealthcare FierceHealthPayer
FierceHealthFinance FierceEMR FiercePracticeManagemtn Hospital Impact

Syndicate content

SEC news from FierceHealthcare

News

Whistleblowers earn big with new SEC rule

Whistleblowers could reap financial benefits with a new rule approved by the Securities and Exchange Commission (SEC) on Wednesday. As part of the Dodd-Frank Wall Street Reform and Consumer Read more...

Ex-Cardinal Health execs settle with SEC

A group of three Cardinal Health executives have agreed to pay $245,000 in civil penalties to resolve a garden-variety financial scandal, one in which they were accused of manipulating and Read more...

WellCare agrees to pay $10M to settle SEC investigation

WellCare Health Plans has agreed to pay the Securities and Exchange Commission $10 million in civil penalties to put an investigation to rest. The company still faces several other federal and state Read more...

UnitedHealth settles SEC charges

Following on the heels of an $895 million class-action suit settlement over stock-option back-dating, UnitedHealth Group has now agreed to settle charges that it violated a myriad of securities laws, Read more...

DaVita subpoenaed by HHS Inspector General

Renal-care firm DaVita has received a subpoena from the HHS Inspector General's office asking for documents related to its use of vitamin D and anemia drugs. The company, which disclosed the request Read more...

WellCare can't file quarterly financial reports

WellCare Health Plans, already under investigation by far too many state and federal agencies, has reported to the Securities and Exchange Commission that it will be unable to file past quarterly Read more...

Press Releases

ARIAD Announces Pricing of Public Offering of Common Stock

Financing to support filings for regulatory approval and global commercialization of ponatinib in patients with resistant or intolerant CML and additional clinical development of its investigational Read more >>

ARIAD Announces Proposed Public Offering of Common Stock

Financing to support filings for regulatory approval and global commercialization of ponatinib in patients with resistant or intolerant CML and additional clinical development of its investigational Read more >>